Industry News
3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose Standards Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that its 3Dimensions™ mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening…
Read More
– Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients – – Drug safety profile of milademetan preliminarily consistent with prior Phase 1 trial – – Protocol amendment planned to…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease, today announced new preclinical data demonstrating proof-of-concept for AB359 as a novel immunotherapy approach for chronic HBV. AB359 is…
Read More
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address…
Read More
Compelling data with STAR0602 demonstrates potent, single agent anti-tumor activity in PD-1 refractory solid tumor models Distinct mechanism of action through expansion of a subset of Vβ T cells with a novel memory phenotype that promotes durable de novo antitumor immune responses STAR0602 slated to initiate Phase 1/2 clinical trial (START-001) in the fourth quarter…
Read More
– Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design – Excerpt from the Press Release: BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time…
Read More
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other…
Read More
– Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks – 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of ≥5% and ≥10%, respectively – XW003 was safe and well tolerated, with an adverse event profile consistent with other…
Read More Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries Excerpt from the Press Release: MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ — MyOme, a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score…
Read More
OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (NASDAQ: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines, today announced…
Read More